CENTRAL TRUST Co purchased a new stake in ABIOMED, Inc. (NASDAQ:ABMD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,855 shares of the medical equipment provider’s stock, valued at approximately $409,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in ABIOMED by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 132,006 shares of the medical equipment provider’s stock worth $14,875,000 after buying an additional 4,990 shares in the last quarter. Envestnet Asset Management Inc. increased its position in ABIOMED by 2.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 2,663 shares of the medical equipment provider’s stock worth $302,000 after buying an additional 60 shares in the last quarter. AQR Capital Management LLC increased its position in ABIOMED by 537.5% in the fourth quarter. AQR Capital Management LLC now owns 55,740 shares of the medical equipment provider’s stock worth $6,281,000 after buying an additional 46,997 shares in the last quarter. Norges Bank purchased a new position in ABIOMED during the fourth quarter worth approximately $53,701,000. Finally, Quadrature Capital Ltd purchased a new position in ABIOMED during the fourth quarter worth approximately $486,000. Institutional investors and hedge funds own 90.47% of the company’s stock.

Shares of ABIOMED, Inc. (ABMD) opened at 145.07 on Monday. ABIOMED, Inc. has a 1-year low of $95.14 and a 1-year high of $147.45. The stock has a market cap of $6.32 billion, a price-to-earnings ratio of 123.99 and a beta of 0.20. The firm has a 50-day moving average price of $139.39 and a 200-day moving average price of $124.08.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, May 4th. The medical equipment provider reported $0.33 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.33. The company had revenue of $124.68 million for the quarter, compared to analyst estimates of $122.82 million. ABIOMED had a return on equity of 12.67% and a net margin of 11.70%. The firm’s revenue for the quarter was up 32.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 earnings per share. Equities analysts forecast that ABIOMED, Inc. will post $1.84 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “CENTRAL TRUST Co Buys New Position in ABIOMED, Inc. (NASDAQ:ABMD)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/central-trust-co-buys-new-position-in-abiomed-inc-nasdaqabmd/1444969.html.

ABMD has been the subject of a number of research reports. Piper Jaffray Companies upgraded ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 target price for the company in a research report on Thursday, April 6th. Leerink Swann increased their target price on ABIOMED from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, March 30th. William Blair reiterated an “outperform” rating on shares of ABIOMED in a research report on Thursday, June 8th. BidaskClub downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 28th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $140.00 target price (up from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. ABIOMED has a consensus rating of “Buy” and a consensus price target of $151.86.

In other ABIOMED news, VP Michael G. Howley sold 18,279 shares of ABIOMED stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $133.56, for a total value of $2,441,343.24. Following the sale, the vice president now owns 62,105 shares in the company, valued at $8,294,743.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael G. Howley sold 600 shares of ABIOMED stock in a transaction on Monday, May 8th. The shares were sold at an average price of $132.84, for a total value of $79,704.00. Following the completion of the sale, the vice president now owns 48,305 shares in the company, valued at approximately $6,416,836.20. The disclosure for this sale can be found here. Insiders have sold 53,629 shares of company stock worth $7,072,580 in the last three months. 7.00% of the stock is currently owned by corporate insiders.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.